Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trialSube Banerjee, Naji Tabet, Peter Bentham et al.|The Lancet|2021Cited by 86
A roadmap to develop dementia research capacity and capability in Pakistan: A model for low‐ and middle‐income countriesIracema Leroi, Mohammad Wasay, Nasim Chaudhry et al.|Alzheimer s & Dementia Translational Research & Clinical Interventions|2019Cited by 20
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Naji Tabet, Nicolas Farina et al.|Health Technology Assessment|2023Cited by 8
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Sube Banerjee, Martín Knapp et al.|International Psychogeriatrics|2022Cited by 4